Item

Russian-developed COVID-19 Vaccine Interim Trial Reports 92% Success Rate

Title (Dublin Core)

Russian-developed COVID-19 Vaccine Interim Trial Reports 92% Success Rate

Description (Dublin Core)

Following initial findings of Pfizer's vaccine being effective in preventing COVID-19 infection in more than 90% of people, Russia says its vaccine has 92% efficacy according to preliminary findings in stage three of the clinical trials. The trial results are based on 20 confirmed COVID-19 cases.

Date (Dublin Core)

November 11, 2020

Creator (Dublin Core)

Polina Ivanova 7 MIN READ

Contributor (Dublin Core)

Tina Chang

Event Identifier (Dublin Core)

HSE

Partner (Dublin Core)

Arizona State University

Type (Dublin Core)

screenshot

Link (Bibliographic Ontology)

https://uk.reuters.com/article/uk-health-coronavirus-russia-vaccine/russia-says-its-sputnik-v-covid-19-vaccine-is-92-effective-idUKKBN27R0Z0
https://web.archive.org/save/https://uk.reuters.com/article/uk-health-coronavirus-russia-vaccine/russia-says-its-sputnik-v-covid-19-vaccine-is-92-effective-idUKKBN27R0Z0

Controlled Vocabulary (Dublin Core)

English Health & Wellness
English Public Health & Hospitals

Curator's Tags (Omeka Classic)

vaccine
Russia
medical trial
Sputnik V
placebo

Contributor's Tags (a true folksonomy) (Friend of a Friend)

Russia
COVID-19
vaccine

Collection (Dublin Core)

English Vaccine Stories

Linked Data (Dublin Core)

Does the COVID-19 Pandemic Trend Influence the Virality of Trends?

Date Submitted (Dublin Core)

11/12/2020

Date Modified (Dublin Core)

11/13/2020
1/31/2021
03/15/2021

Date Created (Dublin Core)

11/11/2020

Item sets

Covid 19
Arizona State University

This item was submitted on November 12, 2020 by Tina Chang using the form “Share Your Story” on the site “A Journal of the Plague Year”: https://covid-19archive.org/s/archive

Click here to view the collected data.

New Tags

I recognize that my tagging suggestions may be rejected by site curators. I agree with terms of use and I accept to free my contribution under the licence CC BY-SA.